Filing Flows › Comparisons › SPRO vs RFL
Spero Therapeutics vs Rafael Holdings: SPRO and RFL compared
Spero Therapeutics is the larger company: $258K of revenue in its latest quarter (Q1 2026) against $244K for Rafael Holdings (Q4 FY26). Rafael Holdings is growing faster (-30% against -96% a year earlier).
Where the money goes: SPRO and RFL
Spero Therapeutics (SPRO) · Q1 2026
Spero Therapeutics, Q1 2026: revenue $258K (-96% year over year), net loss $7.2M, operating cash flow $15.9M. The chart follows the revenue to costs, profit and cash.
Rafael Holdings (RFL) · Q4 FY26
Rafael Holdings, Q4 FY26: revenue $244K (-30% year over year), net loss $8.9M, operating cash flow −$8.4M. The chart follows the revenue to costs, profit and cash.
| Spero Therapeutics (SPRO) | Rafael Holdings (RFL) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q4 FY26 |
| Revenue | $258K | $244K |
| Revenue growth, Y/Y | -96% | -30% |
| Operating margin | n/m | n/m |
| Net earnings | −$7.2M | −$8.9M |
| Operating cash flow | $15.9M | −$8.4M |
Where the revenue comes from
Rafael Holdings
- Product Revenue: $151K (62%)
- Rental – Third Party: $63K (26%)
- Rental – Related Party: $30K (12%)
Questions
Which is bigger, Spero Therapeutics or Rafael Holdings?
Spero Therapeutics is the larger company: $258K of revenue in its latest quarter (Q1 2026) against $244K for Rafael Holdings (Q4 FY26).
Is Spero Therapeutics or Rafael Holdings growing faster?
Rafael Holdings is growing faster (-30% against -96% a year earlier).
More: Spero Therapeutics earnings · how Spero Therapeutics makes money · Rafael Holdings earnings · how Rafael Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 13, 2026; 10-K filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.